Annexon Inc. reports third quarter 2025 results with cash reserves of $188.7 million
Annexon Inc. reported a net loss of $54.9 million, or $0.37 per share, for the third quarter ended September 30, 2025, compared to a net loss of $34.8 million, or $0.25 per share, for the same period in 2024. Research and development expenses rose to $49.7 million from $30.1 million, mainly due to progress in the Phase 3 ARCHER II trial of vonaprument in GA and investments in tanruprubart global filings for GBS. General and administrative expenses decreased to $7.3 million from $9.3 million, reflecting ongoing corporate efficiencies. The company held $188.7 million in cash, cash equivalents, and short-term investments as of September 30, 2025, and expects to fund operations and milestones into late first quarter 2027. Key business developments included anticipated milestones such as the completion of the ANX1502 proof of concept study in 2026 and continued advancement of late-stage clinical programs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572665-en) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.